The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation
| Status: | Withdrawn |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 11/16/2018 |
| Start Date: | June 2015 |
| End Date: | July 2015 |
A Phase 1 Single-dose Open Label 3-way Crossover Study To Evaluate The Bioavailability Of A Spray Dried Dispersion Solid Dose Formulation Of Pf-06260414 Relative To A Suspension Formulation Under Fasted Conditions And The Effect Of Food On The Bioavailability Of The Pf-06260414 Spray Dried Dispersion Solid Formulation In Healthy Subjects
The current study will investigate the relative bioavailability of a spray dried dispersion
solid dose formulation of PF 06260414 administered as a single oral dose of 30 mg of PF
06260414 relative to a single oral dose of 30 mg of PF 06260414 administered as a
nanosuspension under fasted or fed conditions in healthy adult subjects.
solid dose formulation of PF 06260414 administered as a single oral dose of 30 mg of PF
06260414 relative to a single oral dose of 30 mg of PF 06260414 administered as a
nanosuspension under fasted or fed conditions in healthy adult subjects.
Inclusion Criteria:
- Healthy male and/or female subjects of non childbearing potential between the ages of
18 and 55 years, inclusive.
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease
- Any condition possibly affecting drug absorption (eg, gastrectomy)
We found this trial at
1
site
Click here to add this to my saved trials
